2-Hydroxyoleic acid - Lipopharma Therapeutics

Drug Profile

2-Hydroxyoleic acid - Lipopharma Therapeutics

Alternative Names: 2-hydroxy-9-cis octadecenoic - Lipopharma; 2-OHOA - Lipopharma Therapeutics; LP561A1; Minerval

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of the Balearic Islands
  • Developer Lipopharma
  • Class Anorectics; Antineoplastics; Oleic acids
  • Mechanism of Action Membrane lipid modulators; Phosphatidylcholine ceramide phosphocholine transferase stimulants; Ras signal transduction pathway modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glioma; Solid tumours

Most Recent Events

  • 15 Sep 2017 2-hydroxyoleic acid (2-OHOA) is still in phase I/IIa development for Solid tumours including malignant glioma (Lipopharma website, September 2017)
  • 05 Jun 2017 Adverse events data from a phase I/II trial in Solid tumours and Glioma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 02 Jun 2017 Efficacy, adverse events and pharmacokinetics data from a phase I/II trial in Glioma and solid tumours presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top